Epithelial ovarian cancer: Evolution of management in the era of precision medicine-Reference-Cited by-全球学者库

Epithelial ovarian cancer: Evolution of management in the era of precision medicine

Published:2019-05-17 Issue: Volume: Page:
ISSN:0007-9235
Container-title:CA: A Cancer Journal for Clinicians
language:en
Short-container-title:CA A Cancer J Clin

Author:

Lheureux Stephanie¹²,Braunstein Marsela³^ORCID,Oza Amit M.⁴⁵

Affiliation:

1. Clinician Investigator, Bras Drug Development Program; and Staff Medical Oncologist and Gynecology Site Leader, Princess Margaret Cancer CentreUniversity Health Network Toronto ON Canada

2. Assistant ProfessorUniversity of Toronto Toronto ON Canada

3. Scientific Associate, Division of Medical Oncology and Hematology, Princess Margaret Cancer CentreUniversity Health Network Toronto ON Canada

4. Chief, Division of Medical Oncology and Hematology; Director, Cancer Clinical Research Unit; and Director, Bras Drug Development Program, Princess Margaret Cancer CentreUniversity Health Network and Mt. Sinai Health System Toronto ON Canada

5. Professor of MedicineUniversity of Toronto Toronto ON Canada

Publisher

Wiley

Subject

Oncology,Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.3322/caac.21559

Reference171 articles.

1. Cancer statistics, 2018;Siegel RL;CA Cancer J Clin.,2018

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray F;CA Cancer J Clin.,2018

3. The World Ovarian Cancer Coalition.The Every Woman Study Summary Report.2018.worldovariancancercoalition.org/wp-content/uploads/2018/11/WOCC-Every-Woman-Study-Summary-Report-Nov-08.pdf. Accessed February 18 2019.

Cited by 798 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel clinical nomogram for predicting cancer-specific survival in patients with non-serous epithelial ovarian cancer: A real-world analysis based on the Surveillance, Epidemiology, and End Results database and external validation in a tertiary center;Translational Oncology;2024-04

3. High-grade serous carcinoma of unknown primary origin associated with STIC clinically presented as isolated inguinal lymphadenopathy: a case report;Frontiers in Oncology;2024-02-02

4. Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by the Africa Middle East Cancer Inter-group [AMCI];Current Women s Health Reviews;2024-02

5. MAPRE3 as an epigenetic target of EZH2 restricts ovarian cancer proliferation in vitro and in vivo;Experimental Cell Research;2024-02